The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Specificity of HercepTest in Determining HER-2/neu Status of Breast Cancers Using the United States Food and Drug Administration–Approved Scoring System
Open accessAbstract
PURPOSE: To evaluate the specificity of the HercepTest for Immunoenzymatic Staining (Dako Corp, Carpinteria, CA) for determining HER-2/neu protein expression in breast cancer. MATERIALS AND METHODS: Forty-eight invasive breast cancers previously found to be HER-2/neu–negative by two different immunohistochemical (IHC) assays and not amplified for the HER-2/neu gene by fluorescence in situ hybridization were studied using the HercepTest kit. HercepTest was performed according to the manufacturer's guidelines, and the results were scored on a 0 to 3+ scale using the United States Food and Drug Administration (FDA)–approved grading system. In this system, cases scored as 2+ or 3+ are considered HER-2/neu–positive. RESULTS: Among these 48 cases, the IHC score using the FDA-approved scoring system was 0 in four cases (8.3%), 1+ in 16 (33.3%), 2+ in 21 (43.8%), and 3+ in seven (14.6%). Therefore, 58.4% of these cases were categorized as HER-2/neu–positive, and the specificity of the HercepTest kit for HER-2/neu expression was 41.6%. However, with the use of a modified scoring system that took into account the level of staining of nonneoplastic epithelium, the specificity increased to 93.2%. CONCLUSION: Our results indicate that the HercepTest kit, when used in accordance with the manufacturer's guidelines and the FDA-approved scoring system, results in a large proportion of breast cancers being categorized as positive for HER-2/neu protein expression and that many of these seem to be false-positives. Consideration of the level of staining of nonneoplastic epithelium resulted in improved specificity. The current FDA-approved scoring system for HercepTest results should be reevaluated before its widespread use in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
ELSTON, C. W., & ELLIS, I. O. (1991) · Histopathology · doi:10.1111/j.1365-2559.1991.tb00229.x · Cited by 6,175
Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2659 · Cited by 1,067
Ross, J. S., & Fletcher, J. A. (1998) · STEM CELLS · doi:10.1002/stem.160413 · Cited by 985
c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer
Muss, H. B., Thor, A. D., Berry, D. A., Kute, T., Liu, E. T., Koerner, F., Cirrincione, C. T., Budman, D. R., Wood, W. C., Barcos, M., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405053301802 · Cited by 961
Gusterson, B. A., Gelber, R. D., Goldhirsch, A., Price, K. N., Säve-Söderborgh, J., Anbazhagan, R., Styles, J., Rudenstam, C. M., Golouh, R., & Reed, R. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1049 · Cited by 838
erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast Cancer
Thor, A. D., Berry, D. A., Budman, D. R., Muss, H. B., Kute, T., Henderson, I. C., Barcos, M., Cirrincione, C., Edgerton, S., Allred, C., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1346 · Cited by 612
ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization
Kallioniemi, O. P., Kallioniemi, A., Kurisu, W., Thor, A., Chen, L. C., Smith, H. S., Waldman, F. M., Pinkel, D., & Gray, J. W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5321 · Cited by 555
(1996) · PubMed · Cited by 554
Press, M. F., Hung, G., Godolphin, W. J., & Slamon, D. (1994) · PubMed · Cited by 478
Cited by
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858
“ErbB2 protein was determined by IHC as described (Jacobs et al., 1999).”
MethodEllis, M. J., Coop, A., Singh, B., Mauriac, L., Llombert-Cussac, A., Jänicke, F., Miller, W. R., Evans, D. B., Dugan, M., Brady, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3808 · Cited by 1,060
The growing role of precision and personalized medicine for cancer treatment
Krzyszczyk, P., Acevedo, A., Davidoff, E. J., Timmins, L. M., Marrero-Berrios, I., Patel, M., White, C., Lowe, C., Sherba, J. J., Hartmanshenn, C., et al. (2018) · TECHNOLOGY · doi:10.1142/s2339547818300020 · Cited by 698
Semiconductor Quantum Dots for Bioimaging and Biodiagnostic Applications
Kairdolf, B. A., Smith, A. M., Stokes, T. H., Wang, M. D., Young, A. N., & Nie, S. (2013) · Annual Review of Analytical Chemistry · doi:10.1146/annurev-anchem-060908-155136 · Cited by 672
Metadata
- Authors
- Jacobs, T. W., Gown, A. M., Yaziji, H., Barnes, M. J., & Schnitt, S. J.
- Venue
- Journal of Clinical Oncology
- Published
- 1999-07
- Volume
- 17
- Issue
- 7
- Pages
- 1983-1983
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2104528117
- Cited by
- 457
- References
- 21
- FWCI
- 13.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Specificity of HercepTest in Determining HER-2/neu Status of Breast Cancers Using the United States Food and Drug Administration–Approved Scoring System. https://app.cochat.ai/papers/10.1200/jco.1999.17.7.1983
- The paper
- Jacobs, T. W., Gown, A. M., Yaziji, H., Barnes, M. J., & Schnitt, S. J. (1999). Specificity of HercepTest in Determining HER-2/neu Status of Breast Cancers Using the United States Food and Drug Administration–Approved Scoring System. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1999.17.7.1983
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.